EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure

Tuong Le Trong Huynh, Phong Thanh Pham, Hien Dieu Tran, Nhan Dinh Tran, Duong Van Tran, Bao Lam Thai Tran, Khoa Dang Dang Tran, Toan Hoang Ngo, Son Kim Tran

PeerJ · 2024

DOI: 10.7717/peerj.18595 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PeerJ, 2024. Verfasst von Tuong Le Trong Huynh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam. Hauptthemen laut MEDLINE: Uric Acid, Losartan, Benzhydryl Compounds, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors, and Angiotensin II Receptor Antagonists (ARBs) also have the effect of reducing serum uric acid but few studies worldwide assessed.

Objective

Evaluate the effectiveness of serum uric acid lowering treatment of SGLT2 inhibitors, and ARB in heart failure (HF) patients.

Methods

We conducted a cross-sectional analysis study with 8 weeks of follow-up on 733 heart failure (HF) patients treated at Can Tho Central General Hospital from January 2023 to March 2024. Patients enrolled in the study were examined and received losartan (Group A) or dapagliflozin (Group B) monotherapy or losartan and dapagliflozin combined therapy (Group C). The uric acid concentration group was defined into three subgroups with tertile 1 from smallest to quartile (Q) 1, tertile 2 from Q2 to Q3, and tertile 3 from Q3 to the largest value.

Results

After 8 weeks of treatment, the uric acid reduction effect between groups A, B, and C showed that the combination group had the optimal reducing effect compared to losartan and dapagliflozin monotherapy with the mean difference being −229.62 ± 76.65 µmol/L, −217.00 ± 146.17 µmol/L, and −284.43 ± 136.32 µmol/L, respectively. In total, combination therapy showed the best reduction outcome in the population of male, female, patients with type 2 diabetes mellitus (T2DM), and dyslipidemia with the mean difference ranging from −226.21 ± 74.65 µmol/L to −231.85 ± 76.28 µmol/L and −209.62 ± 184.94 µmol/L to −225.75 ± 78.53 µmol/L and −273.02 ± 204.54 µmol/L to −308.93 ± 72.97 µmol/L in group A, B, and C, respectively.

Conclusion

The optimal therapy for reducing uric acid levels in HF patients was the combination of losartan and dapagliflozin, and the effectiveness did not change through sex, T2DM, and dyslipidemia patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uric AcidLosartanBenzhydryl CompoundsHeart FailureGlucosidesDrug Therapy, CombinationSodium-Glucose Transporter 2 InhibitorsHumansMaleFemaleAgedMiddle AgedCross-Sectional StudiesTreatment Outcome

Stichwörter der Autor:innen

Combination therapyDapagliflozinHeart failureLosartanUric acid reduction

Substanzen

dapagliflozinUric AcidLosartanBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology and Rheumatology, Can Tho Central General Hospital, Can Tho, Ninh Kieu, Vietnam.
  • Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Ninh Kieu, Vietnam.

Zitieren

APA

Huynh, T. L. T., Pham, P. T., Tran, H. D., Tran, N. D., Tran, D. V., Tran, B. L. T., Tran, K. D. D., Ngo, T. H., & Tran, S. K. (2024). Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure. PeerJ. https://doi.org/10.7717/peerj.18595

Vancouver

Huynh TLT, Pham PT, Tran HD, Tran ND, Tran DV, Tran BLT, et al. Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure. PeerJ. 2024. doi:10.7717/peerj.18595

BibTeX
@article{Huynh2024,
  author = {Huynh, Tuong Le Trong and Pham, Phong Thanh and Tran, Hien Dieu and Tran, Nhan Dinh and Tran, Duong Van and Tran, Bao Lam Thai and Tran, Khoa Dang Dang and Ngo, Toan Hoang and Tran, Son Kim},
  title = {Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure},
  journal = {PeerJ},
  year = {2024},
  doi = {10.7717/peerj.18595}
}
Kostenlos starten →